B. Charbonnel

发表

Comment expliquer la controverse à propos de l’efficacité/sécurité cardiovasculaire dans les essais cliniques concernant le diabète de type 2 ?

M. Krempf, B. Charbonnel, B. Charbonnel, 2015 .

A direct comparison of long‐ and short‐acting GLP‐1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment

J. Rosenstock, A. Gastaldelli, B. Charbonnel, 2014, Diabetes, obesity & metabolism.